Skip to main content
TipRanks
Go Ultimate75% OFF

Kingworld Medicines Group Ltd. (1110) AI Stock Analysis

0 Followers
HK:1110

Kingworld Medicines Group Ltd.

(HKEX:1110)

Select Model
Rating:55.1Neutral
Price Target:HKD 0.39â–²(2.67% Upside)
Action:reiterated
Date:08/19/26

The stock’s mid-50s score reflects weakening financial quality as thin margins, lower profits, and rising leverage increase risk despite ongoing profitability. Supportive technicals, with the price trending above key short- and medium-term moving averages and moderate momentum, help the score from falling lower. Valuation is only modestly favorable, as a high dividend yield is offset by a not-cheap P/E multiple relative to volatile and currently subdued earnings.

Positive Factors
Stable Gross MarginStable gross margins in the mid-to-high 20% range indicate the company has retained product-level economics despite weaker sales. This provides a base for recovery if distribution volumes improve, because future revenue gains would not start from a materially impaired gross-profit structure.
Negative Factors
Revenue ContractionThe shift from strong revenue growth in 2021–2023 to consecutive declines in 2024 and 2025 signals weakening demand or channel performance. Persistent top-line contraction can reduce operating leverage, limit reinvestment capacity, and make recovery in earnings more difficult.

Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)

-40%-30%-20%-10%0%10%20%HK:1110-26.47%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 221.18M
Dividend Yield
8.45%
Average Volume (3M)
1.90M
Price to Earnings (P/E)
16.9
Beta (1Y)
0.22
Revenue Growth
-13.82%
EPS Growth
112.24%
Country
Hong Kong
Employees
711
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Kingworld Medicines Group Ltd. Business Overview & Revenue Model

Company Description

Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and gene...

How the Company Makes Money

Kingworld Medicines Group Ltd. primarily makes money by selling pharmaceutical and healthcare products through wholesale/distribution and related sales activities. Key revenue streams typically include: (1) distribution/wholesale revenue from purchas...

Kingworld Medicines Group Ltd. Financial Statement Overview

Summary

Revenue and profit have recently declined, with net margin near 1% and earnings more volatile, while rising leverage and inconsistent free cash flow offset a still-profitable, moderately capitalized balance sheet.

Income Statement

42Neutral

Balance Sheet

58Neutral

Cash Flow

50Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue787.87M917.34M1.06B1.08B957.70M847.39M
Gross Profit240.04M247.91M270.45M280.67M277.63M263.60M
EBITDA80.78M82.70M110.77M125.48M118.07M116.00M
Net Income11.47M11.28M41.56M38.10M22.74M30.32M
Balance Sheet
Total Assets1.30B1.44B1.42B1.34B1.26B1.21B
Cash, Cash Equivalents and Short-Term Investments188.35M274.70M249.60M194.03M256.17M198.41M
Total Debt438.04M434.05M402.44M354.43M290.68M238.96M
Total Liabilities648.92M753.86M710.04M638.30M569.15M493.19M
Stockholders Equity596.45M617.97M639.79M619.03M615.58M616.90M
Cash Flow
Free Cash Flow-1.18M54.92M94.73M-63.25M93.64M22.88M
Operating Cash Flow38.39M84.56M135.82M42.28M186.55M81.20M
Investing Cash Flow-15.51M-20.11M-27.64M-120.63M-84.05M-50.84M
Financing Cash Flow-60.57M-30.82M-47.61M4.37M-51.31M-87.20M

Kingworld Medicines Group Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.38

Price Trends

50DMA0.38Negative
100DMA0.40Negative
200DMA0.44Negative

Market Momentum

MACD-0.00Positive
RSI48.16Neutral
STOCH21.21Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.38, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.

Kingworld Medicines Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:1110 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0239HK:023986OutperformHKD 738.59M7.3813.59%8.44%10.63%39.44%
HK:0897HK:089759NeutralHKD 406.75M101.390.34%―-8.30%-44.44%
HK:1110HK:111055NeutralHKD 227.44M16.861.89%8.45%-13.82%112.24%
HK:0858HK:085854NeutralHKD 153.70M-0.14-154.56%―-7.12%-523.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1498HK:149841NeutralHKD 117.69M-3.87-21.66%―-6.71%43.14%
HK:0455HK:045540UnderperformHKD 154.80M-2.21-14.55%―12.89%-2.56%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HK:1110HK:0858HK:0455HK:0897HK:1498HK:0239Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:1110 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:1110Kingworld Medicines Group Ltd.0.38-0.14-26.47%
HK:0858Extrawell Pharmaceutical Holdings Limited0.05-0.03-32.91%
HK:0455Tianda Pharmaceuticals Ltd.0.07-0.05-40.50%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.09-18.89%
HK:1498PuraPharm Corp. Ltd.0.22-0.16-42.11%
HK:0239Pak Fah Yeow International Limited2.370.115.05%

Kingworld Medicines Group Ltd. Corporate Events

Kingworld Medicines Narrows Shareholder Loss Despite Sharp Revenue Decline

Aug 27, 2026

Kingworld Medicines Group Ltd., a pharmaceutical and healthcare products distributor in mainland China with supplementary income from investment properties and equity interests, reported mixed interim results for the six months ended 30 June 2026. Th...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026